On April 16, 2026, Georgia-based biomedical company Femasys announced a strategic partnership with AMI Technologies to introduce its fertility portfolio to the Israeli market. The deal brings two of Femasys's lead products into one of the world's highest-utilization fertility-treatment countries: FemaSeed, a first-line artificial-insemination device, and FemVue, a saline-air ultrasound diagnostic for tubal patency.

Why It Matters

The Femasys–AMI partnership validates a structural bet: fertility care globally is trending toward less-invasive first-line options before couples commit to IVF, and the devices that enable that progression have international growth runways independent of U.S. regulatory chop. For femtech investors, the deal is a reminder that the segment's next leg of growth runs through diagnostics and office-based procedures, not only consumer wearables and tracking apps. For IVF-centric competitors, the Femasys model points to a category compression: a rising share of fertility treatment happens before the IVF cycle, which means the device-assisted pre-IVF step is increasingly where the economics live.

Israel's fertility market is a natural fit for Femasys's positioning. The country offers some of the most extensive publicly funded IVF coverage in the world, with cycles per capita far above OECD averages, and AMI Technologies is an established distributor of reproductive medicine devices into Israeli clinics. FemaSeed offers an artificial-insemination approach aimed at the pre-IVF step — a directed intrauterine insemination designed to reach more eggs before couples move to the more invasive and expensive IVF pathway. FemVue, the tubal-patency diagnostic, replaces hysterosalpingography (HSG) for many patients, using saline-air ultrasound contrast to assess fallopian-tube openness without ionizing radiation.

The geography matters as a growth signal. Femasys is a small-cap medical device company trading on Nasdaq, and international expansion has become a core growth lever amid ongoing U.S. policy volatility around IVF and reproductive medicine. Israel's high fertility-treatment utilization, combined with a publicly funded payer model, creates a market structure that specifically rewards less-invasive pre-IVF interventions — exactly the product category Femasys is built around. The Israeli market entry follows earlier Femasys expansion moves in Europe and South America across 2024-2025.

Sources

Update — 2026-04-20

Initial entry — story first created.